Vaccine and Clinical Trials - 2020 in Review
The CVI is developing vaccines for breast, colon, ovarian, prostate, pancreatic, sarcoma, lung, and bladder cancers. While our early vaccines targeted one cancer specific protein, we now develop vaccines directed at multiple proteins that help specifically target and destroy cancer cells. Our vaccines target proteins that are expressed at abnormally high levels in cancer tissue. We design our vaccines to elicit a specific type of immune system response, known as the Type 1 response, which is known to be effective at killing cancer cells. These methods are unique to the CVI and set us apart from other researchers working on cancer vaccines.
While some of our vaccines are in the discovery and preclinical phases, we have multiple vaccines in Phase 1 and Phase 2 clinical trials with human subjects (see below). We are now combining vaccines with other therapies to increase effectiveness of those treatments. Our ultimate goal is to develop vaccines to prevent cancer in the first place, in addition to treating existing cancer and preventing cancer recurrence.
Select Current CVI Clinical Trials
Phase II study of WOKVAC administered with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy in HER2+ breast cancer
Multicenter Phase II study of WOKVAC to prevent recurrence in patients with HER2+ breast cancer (Moffitt Cancer Center)
Phase I study of the safety & immunogenicity of STEMVAC in HER2 negative advanced breast cancer
Phase II study of immunogenicity STEMVAC in early stage triple negative breast cancer patients
Phase II study of anti-PD-1 checkpoint inhibitor in combination with carboplatin to prevent progression after serologic detection of recurrent ovarian cancer
Phase I study of benefit of PRGN-3005-autologous CAR T cells in adv. stage platinum resist. ovarian cancer (Precigen)
ALPHA-TEA - Phase I dose escalation and expansion trial of alpha-tocopheryloxyacetic acid (α-TEA) in patients with treatment refractory HER2+ metastatic breast cancer (Veana Inc.)
Phase I dose escalation and treatment intensification study of a vaccine-based immunotherapy regimen-2 (VBIR-2) for advanced non-small cell lung cancer and metastatic
triple-negative breast cancer (Pfizer)
Multi-antigen DNA plasmid vaccine that is designed to provide broad antigenic coverage to all molecular breast cancer subtypes
Multi-antigen DNA plasmid vaccine that targets stem cells that can initiate and maintain breast cancer and play a role in drug resistance and metastasis
The CVI is also currently developing vaccines and therapies for other cancers including colon, ovarian, lung, sarcoma, and bladder.